Batavia and KU Leuven join forces to accelerate development of highly promising COVID-19 vaccine


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Batavia and KU Leuven join forces to accelerate development of highly promising COVID-19 vaccine
Batavia will leverage its vaccine development and manufacturing experience together with its high-intensity HIP-Vax manufacturing technology

KU Leuven, a leading research institution and one of the top 50 universities in the world and Batavia Biosciences, a contract development and manufacturing organization focused on delivering sustainable manufacturing solutions in the field of vaccines and oncology, announce their partnership on the development of a vector-based COVID-19 vaccine candidate.

The virology team at the KU Leuven Rega Institute for Medical Research, headed by Prof Dr Johan Neyts, has developed a SARS-CoV-2 vaccine candidate consisting of an attenuated vector carrying the SARS-CoV-2 spike immunogen. The vector is derived from the live-attenuated yellow fever vaccine (YF17D strain), which is a proven safe and effective vaccine, used worldwide to protect more than 500 million people against yellow fever.

The YF17D-SARS-CoV-2 vaccine candidate, tentatively named RegaVax, shows convincing pre-clinical immunogenicity and efficacy data in challenge studies, as recently published in Nature (Sanchez-Felipe et al., 2020). Based on this promising data the research group is now confident to start the next phase of development, heading towards preparation for clinical trials.

To support this activity, KU Leuven has partnered with Batavia Biosciences, a frontrunner in developing highly intensified and low-cost vaccine manufacturing processes. Batavia will leverage its vaccine development and manufacturing experience together with its high-intensity HIP-Vax manufacturing technology to develop a clinical manufacturing process for the vaccine candidate, deliver clinical product and prepare for large-scale commercial supply.

Prof Neyts (Head of the Virology research group at the KU Leuven Rega Institute) commented: “RegaVax is the only COVID-19 vaccine candidate based on the yellow fever vaccine. In preclinical models, for example with hamsters, one single dose appears to be highly efficient in protecting against infection with SARS-CoV-2. We hope that this vaccine, will, like the yellow fever vaccine on which it is based, provide, after a single dose, long-lasting protection against this coronavirus.”

Dr. Menzo Havenga (CEO, Batavia Biosciences) stated: “We are delighted to team up with the group of Prof Neyts as the preclinical data generated by the team at KU Leuven for this vaccine candidate look extremely promising.” Dr Christopher Yallop (COO, Batavia Biosciences) added: “Our HIP-Vax technology is ideally suited to develop and manufacture this vaccine rapidly and cost effectively and we are very much looking forward to work closely with the KU Leuven team to deliver the clinical product and help move this vaccine candidate to licensure.”

The partnership aims to deliver the clinical product and to commence clinical testing in 2021.

Tags : #Batavia #KuLeuven #Covid-19Vaccine #latestPharmaNewsDec5 #HIPVax

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026